| Metric | Q2'25 | Q3'25 | Change |
|---|---|---|---|
| Revenue | $20.7M (+129% YoY) | $39.9M (+222% YoY) | +93% QoQ acceleration, 37% above guidance high-end |
| Revenue Geography Mix | Almost all US-based | 70% US / 30% international | Major international expansion from near-zero |
| Adjusted EBITDA Loss | $36.5M loss | $48.9M loss | +34% QoQ loss expansion |
| R&D Spend | $103.4M | $66.3M | -36% QoQ despite 'nearly doubled YoY' claim |
| Stock-Based Compensation | $99.2M | $72.9M | -27% QoQ moderation |
| GAAP EPS Loss | Not disclosed | $3.58 loss | New disclosure, $2.99 from warrant mark-to-market |
| Cash Position | $1.6B pro forma | $3.5B pro forma | +119% from October $2B raise at $93/share |
| Share Count | Not specified | ~350M by year-end | First specific guidance on dilution |
| 2025 Revenue Guidance | $82M-$100M | $106M-$110M | +6-10% guidance raise, Q4 stronger than Q3 |
| Patents Portfolio | 1,000+ patents pending/granted | 1,100+ patents pending/granted | +10% expansion, 30x since IPO |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.